Close

ALPCO-GeneProof and Thermo Fisher partner to launch TaqPath Menu/GeneProof PCR kits for molecular diagnostics; kits to be released in phases beginning with bloodborne and sexually transmitted infections panels

BRNO, Czech Republic Apr 17, 2023 Press Release 2 min read

Exclusive Industry Insights

By submitting, you agree to our Privacy Policy

Share this article:

BRNO, Czech Republic , April 17, 2023 (press release) –

ALPCO-GeneProof, a global leader in diagnostics, and Thermo Fisher announced a strategic partnership that brings the TaqPath Menu | GeneProof PCR kits to market. The partnership combines the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust supply chain and support systems.

The portfolio to be delivered by Thermo Fisher is comprised of 37 CE-IVD molecular diagnostic assays from ALPCO-GeneProof's portfolio, built on its innovative “one workflow” technology, allowing for ease of use and compatibility with a wide range of qPCR instruments. Thermo Fisher plans to release the TaqPath Menu | GeneProof PCR kits in phases beginning with a panel for bloodborne and sexually transmitted infections (STIs). Additional panels for respiratory infections, transplant and immunocompromised infections, thrombotic mutations, and vector-borne diseases will follow.

Thermo Fisher will officially launch the TaqPath Menu | GeneProof portfolio at ECCMID 2023 held in Copenhagen from April 15-18, 2023 .

Contact:
Polly Mitchell
pmitchell@alpco.com

About ALPCO-GeneProof
ALPCO was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since evolved into a leading producer of novel immunodiagnostic reagents for specialty testing laboratories. In 2022, ALPCO merged with GeneProof, a Czech Republic -based provider of specialty molecular diagnostic solutions. Founded in 2005, GeneProof offers a portfolio of more than 50 IVDD and 6 IVDR PCR test kits for infectious diseases and genetic mutations, as well as a suite of proprietary instrumentation for clinical laboratories of all sizes. For additional information, please visit www.alpco.com and www.geneproof.com.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion . Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen , Fisher Scientific , Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Contact Information:
ALPCO-GeneProof
Polly Mitchell
800-592-5726
Contact via Email
www.alpco.com

Read the full story here: https://www.pr.com/press-release/884605

Press Release Distributed by PR.com

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistribute or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

Stay Ahead of Changes

Don't Wait. Stay Informed.

The world and your industry are changing too fast. You need to know what's happening, and our Legislation Monitor can help. It's a critical resource for anyone who wants to stay ahead of regulatory and legal challenges. Then, discover the other ways that Industry Intelligence Inc. can help your business.

Cookie Preferences

This website uses cookies to enhance your browsing experience, analyze site performance, and deliver personalized content. We use a minimal cookie to remember your preferences. For detailed information about our cookie usage, please review our Privacy Policy.